Abstract: Irisin is a newly discovered muscle factor, the precursors for fibronectin type Ⅲdomain-containing 5（FNDC5）. The expression of the activated receptor 1α （PCG-1α） in the skeletal muscle is induced by exercise, PCG-1α expression in muscle stimulates an increase in expression of FNDC5, which is cleaved and secreted as a newly identified hormone, Irisin. Irisin can drive brown-fat-like development of white fat, increase in energy consumption, reduce body weight, improve glucose tolerance and diet-induced insulin resistance, regulation of glucose and lipid metabolism and energy metabolism. Therefore, Irisin is expected to become a new target for treatment of glucose and lipid metabolism diseases. In this paper, the research on the correlation between Irisin and the metabolic diseases of glucose and lipid was reviewed.